EP2398322A4 - Östrogenrezeptorliganden und verfahren zu ihrer verwendung - Google Patents
Östrogenrezeptorliganden und verfahren zu ihrer verwendungInfo
- Publication number
- EP2398322A4 EP2398322A4 EP10744458A EP10744458A EP2398322A4 EP 2398322 A4 EP2398322 A4 EP 2398322A4 EP 10744458 A EP10744458 A EP 10744458A EP 10744458 A EP10744458 A EP 10744458A EP 2398322 A4 EP2398322 A4 EP 2398322A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- estrogen receptor
- receptor ligands
- ligands
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15470709P | 2009-02-23 | 2009-02-23 | |
US16898309P | 2009-04-14 | 2009-04-14 | |
US26166909P | 2009-11-16 | 2009-11-16 | |
PCT/US2010/025032 WO2010096801A1 (en) | 2009-02-23 | 2010-02-23 | Estrogen receptor ligands and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2398322A1 EP2398322A1 (de) | 2011-12-28 |
EP2398322A4 true EP2398322A4 (de) | 2012-12-05 |
Family
ID=42634248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10744458A Withdrawn EP2398322A4 (de) | 2009-02-23 | 2010-02-23 | Östrogenrezeptorliganden und verfahren zu ihrer verwendung |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2398322A4 (de) |
JP (1) | JP5611991B2 (de) |
KR (3) | KR20150135547A (de) |
CN (1) | CN102413692B (de) |
BR (1) | BR112014004008A2 (de) |
CA (1) | CA2753436C (de) |
IL (1) | IL214805A0 (de) |
MX (1) | MX340753B (de) |
RU (1) | RU2543339C2 (de) |
WO (1) | WO2010096801A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8680055B2 (en) | 2009-06-03 | 2014-03-25 | University Of Southern California | Methods for decreasing steroidogenesis in prostate cancer cells |
IN2014DN01959A (de) * | 2011-08-23 | 2015-05-15 | Gtx Inc | |
WO2013142390A1 (en) * | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
WO2014039820A1 (en) * | 2012-09-07 | 2014-03-13 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
WO2023220117A1 (en) * | 2022-05-10 | 2023-11-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007062230A2 (en) * | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
US20100267773A1 (en) * | 2005-11-28 | 2010-10-21 | Dalton James T | Estrogen receptor ligands and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192310A1 (en) * | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
US20060287282A1 (en) * | 2001-06-25 | 2006-12-21 | Steiner Mitchell S | Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof |
US7601739B2 (en) * | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
-
2010
- 2010-02-23 EP EP10744458A patent/EP2398322A4/de not_active Withdrawn
- 2010-02-23 JP JP2011551292A patent/JP5611991B2/ja not_active Expired - Fee Related
- 2010-02-23 WO PCT/US2010/025032 patent/WO2010096801A1/en active Application Filing
- 2010-02-23 CN CN201080017935.0A patent/CN102413692B/zh not_active Expired - Fee Related
- 2010-02-23 RU RU2011137324/15A patent/RU2543339C2/ru not_active IP Right Cessation
- 2010-02-23 MX MX2011008879A patent/MX340753B/es active IP Right Grant
- 2010-02-23 KR KR1020157033005A patent/KR20150135547A/ko not_active Application Discontinuation
- 2010-02-23 KR KR1020137020249A patent/KR20130101146A/ko active IP Right Grant
- 2010-02-23 CA CA2753436A patent/CA2753436C/en not_active Expired - Fee Related
- 2010-02-23 KR KR1020117022324A patent/KR101458539B1/ko not_active IP Right Cessation
-
2011
- 2011-08-23 IL IL214805A patent/IL214805A0/en unknown
-
2012
- 2012-08-23 BR BR112014004008A patent/BR112014004008A2/pt not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007062230A2 (en) * | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
US20100267773A1 (en) * | 2005-11-28 | 2010-10-21 | Dalton James T | Estrogen receptor ligands and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
HO SHUK-MEI: "Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates", JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 91, 1 January 2004 (2004-01-01), pages 491 - 503, XP002982229, ISSN: 0730-2312, DOI: 10.1002/JCB.10759 * |
See also references of WO2010096801A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN102413692A (zh) | 2012-04-11 |
CN102413692B (zh) | 2015-01-07 |
RU2543339C2 (ru) | 2015-02-27 |
JP5611991B2 (ja) | 2014-10-22 |
MX340753B (es) | 2016-07-25 |
BR112014004008A2 (pt) | 2017-03-28 |
MX2011008879A (es) | 2012-04-30 |
KR20130101146A (ko) | 2013-09-12 |
RU2011137324A (ru) | 2013-03-27 |
KR20150135547A (ko) | 2015-12-02 |
AU2010215809A1 (en) | 2011-09-22 |
EP2398322A1 (de) | 2011-12-28 |
CA2753436A1 (en) | 2010-08-26 |
WO2010096801A1 (en) | 2010-08-26 |
IL214805A0 (en) | 2011-11-30 |
KR101458539B1 (ko) | 2014-11-10 |
CA2753436C (en) | 2016-05-24 |
KR20110131227A (ko) | 2011-12-06 |
JP2012518654A (ja) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250624A0 (en) | Anti-fgfr3 antibodies and methods of using them | |
GB2483736B (en) | Estrogen receptor modulators and uses thereof | |
EP2427479A4 (de) | Antikörper und verfahren zu ihrer verwendung | |
ZA201105791B (en) | New adenosine receptor ligands and uses thereof | |
IL214805A0 (en) | Estrogen receptor ligands and methods of use thereof | |
IL223044A0 (en) | Estrogen receptor modulators and uses thereof | |
IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
EP2464227A4 (de) | Verbindungen und anwendungsverfahren dafür | |
EP2543008A4 (de) | Verfahren und vorrichtungen zur erleichterung einer standortauswahl | |
EP2538780A4 (de) | Östrogenrezeptorliganden und verfahren zu ihrer verwendung | |
IL219136A0 (en) | Anti-hepsin antibodies and methods using same | |
EP2419561A4 (de) | Beschichteter stoff und zugehörige verfahren | |
EP2406244A4 (de) | Östrogenverbindungen und verfahren zu ihrer verwendung | |
GB2467764B (en) | Attachment means and methods | |
IL231070A0 (en) | Estrogen receptor ligands and methods of their use | |
GB201011673D0 (en) | Up and down bowl | |
HK1174620A1 (zh) | 吲唑基取代的二氫異噁唑並吡啶及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110923 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1159422 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121106 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 43/40 20060101AFI20121030BHEP Ipc: A61K 31/55 20060101ALI20121030BHEP Ipc: A61K 31/445 20060101ALI20121030BHEP |
|
17Q | First examination report despatched |
Effective date: 20130705 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20161112 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1159422 Country of ref document: HK |